4-anisyltetrazolium-blue and Carcinoma--Hepatocellular

4-anisyltetrazolium-blue has been researched along with Carcinoma--Hepatocellular* in 1 studies

Other Studies

1 other study(ies) available for 4-anisyltetrazolium-blue and Carcinoma--Hepatocellular

Article	Year
A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer gene therapy, 2006, Volume: 13, Issue:2 We constructed a novel hepatocellular carcinoma-specific conditionally replicative adenovirus (CRAd). This adenovirus, designated Ad.HS4.AFP.E1A/TRAIL, expresses E1A to mediate viral replication and TRAIL to enhance HCC-killing efficacy under the control of a modified AFP promoter. An insulator HS-4 was placed in front of the AFP promoter to enhance the fidelity of the heterologous promoter. This virus was shown to have specific cytolytic activity in AFP-expressing HCC cells in vitro. Furthermore, the replication efficiency of Ad.HS4.AFP.E1A/TRAIL correlated well with AFP expression of the host cells, showing a 100-fold and 1 000 000-fold decrease in the low-and non-AFP-expressing HCC cells, respectively, compared to the high AFP-expressing HCC cells. An increase in mRNA of TRAIL and the elevated Caspase-3 activity were also observed in Ad.HS4.AFP.E1A/TRAIL-infected HCC cells. These results indicated that TRAIL expression from the viral vector activated the Caspase-3 enzymatic capacity and the HCC cells were sensitive to TRAIL. In vivo, Ad.HS4.AFP.E1A/TRAIL effectively prevented the growth of low AFP-expressing BEL-7404 xenografts. These results indicate that Ad.HS4.AFP.E1A/TRAIL could provide a new strategy of gene therapy for HCC. Topics: Adenoviridae; alpha-Fetoproteins; Animals; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Caspase 3; Caspases; Cell Line, Tumor; Colorimetry; DNA Primers; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha	2006

Article

Year

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma.

Cancer gene therapy, 2006, Volume: 13, Issue:2

We constructed a novel hepatocellular carcinoma-specific conditionally replicative adenovirus (CRAd). This adenovirus, designated Ad.HS4.AFP.E1A/TRAIL, expresses E1A to mediate viral replication and TRAIL to enhance HCC-killing efficacy under the control of a modified AFP promoter. An insulator HS-4 was placed in front of the AFP promoter to enhance the fidelity of the heterologous promoter. This virus was shown to have specific cytolytic activity in AFP-expressing HCC cells in vitro. Furthermore, the replication efficiency of Ad.HS4.AFP.E1A/TRAIL correlated well with AFP expression of the host cells, showing a 100-fold and 1 000 000-fold decrease in the low-and non-AFP-expressing HCC cells, respectively, compared to the high AFP-expressing HCC cells. An increase in mRNA of TRAIL and the elevated Caspase-3 activity were also observed in Ad.HS4.AFP.E1A/TRAIL-infected HCC cells. These results indicated that TRAIL expression from the viral vector activated the Caspase-3 enzymatic capacity and the HCC cells were sensitive to TRAIL. In vivo, Ad.HS4.AFP.E1A/TRAIL effectively prevented the growth of low AFP-expressing BEL-7404 xenografts. These results indicate that Ad.HS4.AFP.E1A/TRAIL could provide a new strategy of gene therapy for HCC.

Topics: Adenoviridae; alpha-Fetoproteins; Animals; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Caspase 3; Caspases; Cell Line, Tumor; Colorimetry; DNA Primers; Female; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Tetrazolium Salts; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2006